ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,108Medicare Part D Prescriptions Filled, Including Refills

Rank: 71 out of 1269

$570K Total Retail Price of All Prescriptions

Rank: 109 out of 1269

455 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
41% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 455 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

6% of this provider’s 455 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 9,457 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LEVOTHYROXINE SODIUM 383 381 1 4
LISINOPRIL 328 323 2 1
METOPROLOL SUCCINATE 302 295 3 13
SIMVASTATIN 289 270 4 3
OMEPRAZOLE 287 262 5 8
FUROSEMIDE 277 251 6 5
METOPROLOL TARTRATE 270 247 7 6
CITALOPRAM HBR 260 260 8 21
AMLODIPINE BESYLATE 233 222 9 2
GABAPENTIN 205 180 10 17
DONEPEZIL HCL 186 186 11 22
HYDROCHLOROTHIAZIDE 168 152 12 10
MIRTAZAPINE 147 147 13 24
SERTRALINE HCL 138 130 14 23
WARFARIN SODIUM 130 128 15 12
ALENDRONATE SODIUM 126 126 16 28
NAMENDA 122 122 17 38
TRAMADOL HCL 121 121 18 16
PANTOPRAZOLE SODIUM 120 117 19 18
LOVASTATIN 118 118 20 30
ZOLPIDEM TARTRATE 118 111 20 19
PRAVASTATIN SODIUM 105 99 22 11
AZITHROMYCIN 104 91 23 42
ATORVASTATIN CALCIUM 104 98 23 7
LOSARTAN POTASSIUM 98 98 25 15
CYMBALTA 97 82 26 70
METFORMIN HCL 93 72 27 9
TRAZODONE HCL 83 68 28 36
CLOPIDOGREL 76 73 29 32
CARVEDILOL 75 75 30 29
ESCITALOPRAM OXALATE 72 72 31 58
RANITIDINE HCL 70 63 32 27
KLOR-CON M20 68 66 33 60
HYDROCODONE-ACETAMINOPHEN 67 60 S3 34 20
GLIMEPIRIDE 66 65 35 57
NAPROXEN 65 64 36 107
GLYBURIDE 63 52 R 37 94
DIGOXIN 62 62 38 62
PLAVIX 57 54 39 47
ZETIA 56 54 40 99
NEXIUM 56 53 40 41
PAROXETINE HCL 55 55 42 71
RISPERIDONE 55 54 42 43
ALLOPURINOL 54 45 44 49
DIVALPROEX SODIUM 53 49 45 54
CELEBREX 53 38 45 95
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 15, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.